title: Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes.
abstract: Prostate cancer is currently the most commonly diagnosed noncutaneous malignancy in American men. When metastatic, usually to the bone, the disease is no longer curable and is usually treated palliatively with androgen ablation. However, after conversion to androgen-independent disease, there is no effective therapy currently available. The "T body" approach, which uses genetically reprogrammed lymphocytes derived from the patient and expressing chimeric receptor genes, combines the effector functions of T lymphocytes and NK cells with the ability of antibodies to recognize predefined surface antigens with high specificity and in a non-MHC-restricted manner. We show here the therapeutic efficacy of human lymphocytes bearing erbB2-specific chimeric receptors on human prostate cancer BM lesions in a SCID mouse model after conditioning of the recipient to allow homing and persistent functioning of the adoptively transferred cells. Induction of stromal cell-derived factor-1 production within the BM using low-dose irradiation or cyclophosphamide combined with IL-2 administration enhanced the homing of systemically delivered T bodies, resulting in decreased tumor growth and prostate-specific antigen secretion, prolongation of survival, and even cure of the treated mice. These preclinical studies strongly support the idea that the T body approach has therapeutic potential in disseminated prostate cancer.
authors.affiliation: Department of Immunology, The Weizmann Institute of Science, Rehovot 76100, Israel.
authors.forename: Jehonathan H
authors.initials: JH
authors.lastname: Pinthus
authors.forename: Tova
authors.initials: T
authors.lastname: Waks
authors.forename: Victoria
authors.initials: V
authors.lastname: Malina
authors.forename: Keren
authors.initials: K
authors.lastname: Kaufman-Francis
authors.forename: Alon
authors.initials: A
authors.lastname: Harmelin
authors.forename: Itzhak
authors.initials: I
authors.lastname: Aizenberg
authors.forename: Hannah
authors.initials: H
authors.lastname: Kanety
authors.forename: Jacob
authors.initials: J
authors.lastname: Ramon
authors.forename: Zelig
authors.initials: Z
authors.lastname: Eshhar
mesh_terms: D000818:Animals; D018906:Antineoplastic Agents, Alkylating / Q000494:pharmacology; D001859:Bone Neoplasms / Q000556:secondary* / Q000628:therapy; D002465:Cell Movement; D002469:Cell Separation; D002470:Cell Survival; D003520:Cyclophosphamide / Q000494:pharmacology; D005434:Flow Cytometry; D006801:Humans; D016219:Immunotherapy, Adoptive / Q000379:methods*; D007376:Interleukin-2 / Q000378:metabolism; D008214:Lymphocytes / Q000378:metabolism*; D008297:Male; D051379:Mice; D016513:Mice, SCID; D009368:Neoplasm Transplantation; D017430:Prostate-Specific Antigen / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000473:pathology* / Q000628:therapy*; D012313:RNA / Q000737:chemistry; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013997:Time Factors
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003520:Cyclophosphamide; D007376:Interleukin-2; D017430:Prostate-Specific Antigen; D012313:RNA; D018719:Erb-b2 Receptor Tyrosine Kinases